Loading
Yanuki
SUBCATEGORY FEED
Intellia Therapeutics Pauses CRISPR Gene-Editing Trials Due to Safety Concerns | Lyra Therapeutics' LYR-210 Shows Positive Phase 3 Results for Chronic Rhinosinusitis | Spero Therapeutics and GSK's Oral UTI Treatment Shows Promising Results | Intellia Therapeutics Pauses CRISPR Gene-Editing Trials Due to Safety Concerns | Lyra Therapeutics' LYR-210 Shows Positive Phase 3 Results for Chronic Rhinosinusitis | Spero Therapeutics and GSK's Oral UTI Treatment Shows Promising Results

News / Clinical Trials

Intellia Therapeutics Pauses CRISPR Gene-Editing Trials Due to Safety Concerns

Intellia Therapeutics (NASDAQ:NTLA) has temporarily paused patient dosing and screening in its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran (nex-z) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and...

Intellia Therapeutics Pauses CRISPR Gene-Editing Trials Due to Safety Concerns Image via Intellia Therapeutics
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Crime Weather Politics Local Lottery Local News Legal Education Accidents Immigration